Arginase-2 mediates renal ischemia-reperfusion injury

Wesley M. Raup-Konsavage, Ting Gao, Timothy K. Cooper, Sidney M. Morris, William B Reeves, Alaa S Awad

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Novel therapeutic interventions for preventing or attenuating kidney injury following ischemia-reperfusion injury (IRI) remain a focus of significant interest. Currently, there are no definitive therapeutic or preventive approaches available for ischemic acute kidney injury (AKI). Our objective is to determine 1) whether renal arginase activity or expression is increased in renal IRI, and 2) whether arginase plays a role in development of renal IRI. The impact of arginase activity and expression on renal damage was evaluated in male C57BL/6J (wild type) and arginase-2 (ARG2)-deficient (Arg2-/-) mice subjected to bilateral renal ischemia for 28 min, followed by reperfusion for 24 h. ARG2 expression and arginase activity significantly increased following renal IRI, paralleling the increase in kidney injury. Pharmacological blockade or genetic deficiency of Arg2 conferred kidney protection in renal IRI. Arg2-/- mice had significantly attenuated kidney injury and lower plasma creatinine and blood urea nitrogen levels after renal IRI. Blocking arginases using S-(2-boronoethyl)-L-cysteine (BEC) 18 h before ischemia mimicked arginase deficiency by reducing kidney injury, histopathological changes and kidney injury mar-ker-1 expression, renal apoptosis, kidney inflammatory cell recruitment and inflammatory cytokines, and kidney oxidative stress; increasing kidney nitric oxide (NO) production and endothelial NO synthase (eNOS) phosphorylation, kidney peroxisome proliferator-activated receptor-γ coactivator-1α expression, and mitochondrial ATP; and preserving kidney mitochondrial ultrastructure compared with vehicle-treated IRI mice. Importantly, BEC-treated eNOS-knockout mice failed to reduce blood urea nitrogen and creatinine following renal IRI. These findings indicate that ARG2 plays a major role in renal IRI, via an eNOS-dependent mechanism, and that blocking ARG2 activity or expression could be a novel therapeutic approach for prevention of AKI.

Original languageEnglish (US)
Pages (from-to)F522-F534
JournalAmerican Journal of Physiology - Renal Physiology
Volume313
Issue number2
DOIs
StatePublished - Aug 10 2017

Fingerprint

Arginase
Reperfusion Injury
Kidney
Wounds and Injuries
Blood Urea Nitrogen
Acute Kidney Injury
Nitric Oxide Synthase
Hyperargininemia
Creatinine
Ischemia

Keywords

  • Arginase
  • Ischemia-reperfusion
  • Mitochondria
  • Nitric oxide

ASJC Scopus subject areas

  • Physiology
  • Urology

Cite this

Arginase-2 mediates renal ischemia-reperfusion injury. / Raup-Konsavage, Wesley M.; Gao, Ting; Cooper, Timothy K.; Morris, Sidney M.; Reeves, William B; Awad, Alaa S.

In: American Journal of Physiology - Renal Physiology, Vol. 313, No. 2, 10.08.2017, p. F522-F534.

Research output: Contribution to journalArticle

Raup-Konsavage, Wesley M. ; Gao, Ting ; Cooper, Timothy K. ; Morris, Sidney M. ; Reeves, William B ; Awad, Alaa S. / Arginase-2 mediates renal ischemia-reperfusion injury. In: American Journal of Physiology - Renal Physiology. 2017 ; Vol. 313, No. 2. pp. F522-F534.
@article{4fc499be1f974e90bf20fc82bc187521,
title = "Arginase-2 mediates renal ischemia-reperfusion injury",
abstract = "Novel therapeutic interventions for preventing or attenuating kidney injury following ischemia-reperfusion injury (IRI) remain a focus of significant interest. Currently, there are no definitive therapeutic or preventive approaches available for ischemic acute kidney injury (AKI). Our objective is to determine 1) whether renal arginase activity or expression is increased in renal IRI, and 2) whether arginase plays a role in development of renal IRI. The impact of arginase activity and expression on renal damage was evaluated in male C57BL/6J (wild type) and arginase-2 (ARG2)-deficient (Arg2-/-) mice subjected to bilateral renal ischemia for 28 min, followed by reperfusion for 24 h. ARG2 expression and arginase activity significantly increased following renal IRI, paralleling the increase in kidney injury. Pharmacological blockade or genetic deficiency of Arg2 conferred kidney protection in renal IRI. Arg2-/- mice had significantly attenuated kidney injury and lower plasma creatinine and blood urea nitrogen levels after renal IRI. Blocking arginases using S-(2-boronoethyl)-L-cysteine (BEC) 18 h before ischemia mimicked arginase deficiency by reducing kidney injury, histopathological changes and kidney injury mar-ker-1 expression, renal apoptosis, kidney inflammatory cell recruitment and inflammatory cytokines, and kidney oxidative stress; increasing kidney nitric oxide (NO) production and endothelial NO synthase (eNOS) phosphorylation, kidney peroxisome proliferator-activated receptor-γ coactivator-1α expression, and mitochondrial ATP; and preserving kidney mitochondrial ultrastructure compared with vehicle-treated IRI mice. Importantly, BEC-treated eNOS-knockout mice failed to reduce blood urea nitrogen and creatinine following renal IRI. These findings indicate that ARG2 plays a major role in renal IRI, via an eNOS-dependent mechanism, and that blocking ARG2 activity or expression could be a novel therapeutic approach for prevention of AKI.",
keywords = "Arginase, Ischemia-reperfusion, Mitochondria, Nitric oxide",
author = "Raup-Konsavage, {Wesley M.} and Ting Gao and Cooper, {Timothy K.} and Morris, {Sidney M.} and Reeves, {William B} and Awad, {Alaa S}",
year = "2017",
month = "8",
day = "10",
doi = "10.1152/ajprenal.00620.2016",
language = "English (US)",
volume = "313",
pages = "F522--F534",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "0363-6127",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Arginase-2 mediates renal ischemia-reperfusion injury

AU - Raup-Konsavage, Wesley M.

AU - Gao, Ting

AU - Cooper, Timothy K.

AU - Morris, Sidney M.

AU - Reeves, William B

AU - Awad, Alaa S

PY - 2017/8/10

Y1 - 2017/8/10

N2 - Novel therapeutic interventions for preventing or attenuating kidney injury following ischemia-reperfusion injury (IRI) remain a focus of significant interest. Currently, there are no definitive therapeutic or preventive approaches available for ischemic acute kidney injury (AKI). Our objective is to determine 1) whether renal arginase activity or expression is increased in renal IRI, and 2) whether arginase plays a role in development of renal IRI. The impact of arginase activity and expression on renal damage was evaluated in male C57BL/6J (wild type) and arginase-2 (ARG2)-deficient (Arg2-/-) mice subjected to bilateral renal ischemia for 28 min, followed by reperfusion for 24 h. ARG2 expression and arginase activity significantly increased following renal IRI, paralleling the increase in kidney injury. Pharmacological blockade or genetic deficiency of Arg2 conferred kidney protection in renal IRI. Arg2-/- mice had significantly attenuated kidney injury and lower plasma creatinine and blood urea nitrogen levels after renal IRI. Blocking arginases using S-(2-boronoethyl)-L-cysteine (BEC) 18 h before ischemia mimicked arginase deficiency by reducing kidney injury, histopathological changes and kidney injury mar-ker-1 expression, renal apoptosis, kidney inflammatory cell recruitment and inflammatory cytokines, and kidney oxidative stress; increasing kidney nitric oxide (NO) production and endothelial NO synthase (eNOS) phosphorylation, kidney peroxisome proliferator-activated receptor-γ coactivator-1α expression, and mitochondrial ATP; and preserving kidney mitochondrial ultrastructure compared with vehicle-treated IRI mice. Importantly, BEC-treated eNOS-knockout mice failed to reduce blood urea nitrogen and creatinine following renal IRI. These findings indicate that ARG2 plays a major role in renal IRI, via an eNOS-dependent mechanism, and that blocking ARG2 activity or expression could be a novel therapeutic approach for prevention of AKI.

AB - Novel therapeutic interventions for preventing or attenuating kidney injury following ischemia-reperfusion injury (IRI) remain a focus of significant interest. Currently, there are no definitive therapeutic or preventive approaches available for ischemic acute kidney injury (AKI). Our objective is to determine 1) whether renal arginase activity or expression is increased in renal IRI, and 2) whether arginase plays a role in development of renal IRI. The impact of arginase activity and expression on renal damage was evaluated in male C57BL/6J (wild type) and arginase-2 (ARG2)-deficient (Arg2-/-) mice subjected to bilateral renal ischemia for 28 min, followed by reperfusion for 24 h. ARG2 expression and arginase activity significantly increased following renal IRI, paralleling the increase in kidney injury. Pharmacological blockade or genetic deficiency of Arg2 conferred kidney protection in renal IRI. Arg2-/- mice had significantly attenuated kidney injury and lower plasma creatinine and blood urea nitrogen levels after renal IRI. Blocking arginases using S-(2-boronoethyl)-L-cysteine (BEC) 18 h before ischemia mimicked arginase deficiency by reducing kidney injury, histopathological changes and kidney injury mar-ker-1 expression, renal apoptosis, kidney inflammatory cell recruitment and inflammatory cytokines, and kidney oxidative stress; increasing kidney nitric oxide (NO) production and endothelial NO synthase (eNOS) phosphorylation, kidney peroxisome proliferator-activated receptor-γ coactivator-1α expression, and mitochondrial ATP; and preserving kidney mitochondrial ultrastructure compared with vehicle-treated IRI mice. Importantly, BEC-treated eNOS-knockout mice failed to reduce blood urea nitrogen and creatinine following renal IRI. These findings indicate that ARG2 plays a major role in renal IRI, via an eNOS-dependent mechanism, and that blocking ARG2 activity or expression could be a novel therapeutic approach for prevention of AKI.

KW - Arginase

KW - Ischemia-reperfusion

KW - Mitochondria

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=85027258357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027258357&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00620.2016

DO - 10.1152/ajprenal.00620.2016

M3 - Article

C2 - 28515179

AN - SCOPUS:85027258357

VL - 313

SP - F522-F534

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 0363-6127

IS - 2

ER -